Investigational drug · Phase 2
NM8074
Not approved by FDA. In 8 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Paroxysmal Nocturnal Hemoglobinuria, Dermatomyositis, PNH - Paroxysmal Nocturnal Hemoglobinuria.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
8
8 still active
All registered trials
9
Any phase or sponsor naming "NM8074"
First trial start
2026
Apr 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NM8074", any sponsor or status.
Conditions studied
As listed on its trial records.
- Paroxysmal Nocturnal Hemoglobinuria
- Dermatomyositis
- PNH - Paroxysmal Nocturnal Hemoglobinuria
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- aHUS - Atypical Hemolytic Uremic Syndrome
- IgA Nephropathy
- C3 Glomerulopathy
Approved drugs for the same conditions: Paroxysmal nocturnal hemoglobinuria · IgA nephropathy · Immunology and inflammation · Rare and genetic disease · Kidney and urology · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "NM8074" as an intervention, largest first.
NovelMed TherapeuticsIndustry
NCT05642546 · 40 participants · Start Aug 12, 2020 · Primary completion Jun 15, 2022
Drug: NM8074; Placebo · For: Healthy
Sites: Dallas, Texas
- Study of NM8074 in Adult C3 Glomerulopathy PatientsNot yet recruiting
NovelMed TherapeuticsIndustry
NCT05647811 · 18 participants (planned) · Start May 2027 · Primary completion Aug 2029
Drug: NM8074 · For: C3 Glomerulopathy
- Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV)Not yet recruiting
NovelMed TherapeuticsIndustry
NCT06226662 · 12 participants (planned) · Start Jun 2026 · Primary completion Oct 2027
Drug: NM8074; Placebo · For: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic MicroangiopathyNot yet recruiting
NovelMed TherapeuticsIndustry
NCT05684159 · 12 participants (planned) · Start Nov 2027 · Primary completion Apr 2030
Drug: NM8074 · For: aHUS - Atypical Hemolytic Uremic Syndrome
NovelMed TherapeuticsIndustry
NCT05646563 · 12 participants (planned) · Start Jan 2027 · Primary completion Jul 2029
Drug: NM8074; Soliris · For: Paroxysmal Nocturnal Hemoglobinuria
- Study of Efficacy and Safety of NM8074 in Adult PNH Patients Who Are Naive to Complement Inhibitor TherapyNot yet recruiting
NovelMed TherapeuticsIndustry
NCT05646524 · 12 participants (planned) · Start Apr 2026 · Primary completion Aug 2027
Drug: NM8074 · For: Paroxysmal Nocturnal Hemoglobinuria
- Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN)Not yet recruiting
NovelMed TherapeuticsIndustry
NCT06454110 · 10 participants (planned) · Start Feb 2028 · Primary completion Dec 2030
Drug: NM8074 · For: IgA Nephropathy
- Study of NM8074 in Patients with Dermatomyositis (DM)Not yet recruiting
NovelMed TherapeuticsIndustry
NCT06887738 · 8 participants (planned) · Start Jun 2026 · Primary completion Nov 2027
Drug: NM8074 · For: Dermatomyositis
- Study of NM8074 in Soliris-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)Not yet recruiting
NovelMed TherapeuticsIndustry
NCT05731050 · 6 participants (planned) · Start Jun 2026 · Primary completion Sep 2027
Drug: NM8074 · For: PNH - Paroxysmal Nocturnal Hemoglobinuria
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Paroxysmal Nocturnal Hemoglobinuria
- HRS-5965Phase 36 trials
Chengdu Suncadia Medicine Co., Ltd. · Primary IgA Nephropathy, Paroxysmal Nocturnal Hemoglobinuria
- CemdisiranALN-CC5Phase 35 trials
Regeneron · Paroxysmal Nocturnal Hemoglobinuria, Generalized Myasthenia Gravis, Age-related Macular Degeneration (AMD)
- HSK39297Phase 35 trials
Haisco Pharmaceutical Group Co., Ltd. · IgA Nephropathy (IgAN), Paroxysmal Nocturnal Hemoglobinuria, Paroxysmal Nocturnal Haemoglobinuria (PNH)
- MY008211APhase 35 trials
Wuhan Createrna Science and Technology Co., Ltd · Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy (IgAN)
- FXS6837Phase 34 trials
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Paroxysmal Nocturnal Hemoglobinuria, Primary IgAN, IgAN
- NTQ5082Phase 34 trials
Nanjing Chia-tai Tianqing Pharmaceutical · Paroxysmal Nocturnal Hemoglobinuria, Primary IgA Nephropathy
- LP-005Phase 24 trials
Longbio Pharma · Periodontitis, Paroxysmal Nocturnal Hemoglobinuria, Complement-mediated Renal Diseases
- HS-10542Phase 22 trials
Jiangsu Hansoh Pharmaceutical Co., Ltd. · IgAN, Immunoglobulin A Nephropathy (IgAN), Glomerular Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.